Page last updated: 2024-12-06

n-ethyl-n-(4-hydroxybutyl)nitrosamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N-ethyl-N-(4-hydroxybutyl)nitrosamine: rapid & selective inducer of urinary bladder cancer in rats [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID41223
SCHEMBL ID105573
MeSH IDM0056453

Synonyms (22)

Synonym
brn 2240539
n-ethyl-n-(4-hydroxybutyl)nitrosoamine
ehbn
1-butanol, 4-(ethylnitrosoamino)-
n-ethyl-n-(4-hydroxybutyl)nitrosamine
ccris 1023
n-ethyl-n-(4-hydroxybutyl)nitrous amide
FT-0692394
n-ethyl-n-butan-4-ol-nitrosamine
n-ethyl-n-nitroso-4-aminobutanol
E0307
54897-62-0
unii-1bl5t2e6yf
1bl5t2e6yf ,
SCHEMBL105573
SAWPRHGGVOPPSR-UHFFFAOYSA-N
4-(1-ethyl-2-oxohydrazino)-1-butanol #
DTXSID70203384
T72602
BS-52935
4-(n-ethyl-n-nitrosoamino)-1-butanol
ethyl-n-(4-hydroxybutyl)nitrosoamine, n-
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (15)

TimeframeStudies, This Drug (%)All Drugs %
pre-19907 (46.67)18.7374
1990's8 (53.33)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.70

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.70 (24.57)
Research Supply Index2.77 (2.92)
Research Growth Index4.48 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.70)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other15 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]